NO20052009L - Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom - Google Patents
Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndromInfo
- Publication number
- NO20052009L NO20052009L NO20052009A NO20052009A NO20052009L NO 20052009 L NO20052009 L NO 20052009L NO 20052009 A NO20052009 A NO 20052009A NO 20052009 A NO20052009 A NO 20052009A NO 20052009 L NO20052009 L NO 20052009L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- myelodysplastic syndrome
- acute leukemia
- combination therapy
- pharmaceutical combinations
- Prior art date
Links
- 206010000830 Acute leukaemia Diseases 0.000 title abstract 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 abstract 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 abstract 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 abstract 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 229940045799 anthracyclines and related substance Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229960000684 cytarabine Drugs 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 229960000975 daunorubicin Drugs 0.000 abstract 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 abstract 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 abstract 1
- 150000003834 purine nucleoside derivatives Chemical class 0.000 abstract 1
- 239000002718 pyrimidine nucleoside Substances 0.000 abstract 1
Classifications
-
- E—FIXED CONSTRUCTIONS
- E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
- E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
- E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices
- E05F3/04—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes
- E05F3/10—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction
- E05F3/108—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction with piston rod protruding from the closer housing; Telescoping closers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- E—FIXED CONSTRUCTIONS
- E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
- E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
- E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2002/035532 WO2004043461A1 (en) | 2002-11-06 | 2002-11-06 | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20052009D0 NO20052009D0 (no) | 2005-04-25 |
| NO20052009L true NO20052009L (no) | 2005-06-27 |
Family
ID=32311637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20052009A NO20052009L (no) | 2002-11-06 | 2005-04-25 | Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1575582A4 (es) |
| JP (1) | JP2006508119A (es) |
| CN (1) | CN1720044A (es) |
| AU (2) | AU2002348178A1 (es) |
| BR (1) | BR0215935A (es) |
| CA (1) | CA2504611A1 (es) |
| CR (1) | CR7804A (es) |
| MX (1) | MXPA05004711A (es) |
| NO (1) | NO20052009L (es) |
| WO (1) | WO2004043461A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7977320B2 (en) | 2004-10-29 | 2011-07-12 | The Regents Of The University Of California | Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents |
| EP1661584A1 (en) * | 2004-11-26 | 2006-05-31 | Heinz Dr. Faulstich | Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy |
| CA2614321A1 (en) * | 2005-07-06 | 2007-01-18 | Kanisa Pharmaceuticals, Inc. | Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar |
| ATE521366T1 (de) * | 2006-05-27 | 2011-09-15 | Faulstich Heinz Dr | Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen |
| CN1994293A (zh) * | 2006-08-18 | 2007-07-11 | 上海交通大学医学院附属瑞金医院 | 冬凌草甲素在制药中的应用 |
| US20110038856A1 (en) * | 2006-11-02 | 2011-02-17 | Seattle Genetics, Inc. | Methods of treating neoplastic, autoimmune and inflammatory diseases |
| PT2120568T (pt) * | 2007-02-16 | 2017-12-04 | Celator Pharmaceuticals Inc | Rácios de fármacos fixados para tratamento de cancros hematopoiéticos e desordens proliferativas |
| CA2708264C (en) | 2007-12-10 | 2018-07-03 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
| WO2010024374A1 (ja) | 2008-08-29 | 2010-03-04 | 学校法人北里研究所 | Ｄｎａメチル化阻害剤の薬剤効果検出方法 |
| US12071450B2 (en) | 2015-12-03 | 2024-08-27 | Biosight Ltd. | Salts of conjugates for cancer therapy |
| US12064445B2 (en) | 2015-12-03 | 2024-08-20 | Biosight Ltd. | Cytarabine conjugates for cancer therapy |
| WO2017160954A1 (en) | 2016-03-15 | 2017-09-21 | Seattle Genetics, Inc. | Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors |
| WO2017210621A1 (en) * | 2016-06-03 | 2017-12-07 | Seattle Genetics, Inc. | Combination of cd33 antibody drug conjugates with chemotherapeutic agents |
| WO2017214433A1 (en) | 2016-06-09 | 2017-12-14 | Seattle Genetics, Inc. | Combinations of pbd-based antibody drug conjugates with flt3 inhibitors |
| IL271475B2 (en) * | 2017-06-22 | 2023-09-01 | Servier Lab | Combination of mcl-1 inhibitor and standard medical treatment for hematological cancer, uses and pharmaceutical preparations |
| IL271946B (en) * | 2017-07-09 | 2022-09-01 | Biosight Ltd | Combination cancer therapy |
| BR112021014625A2 (pt) * | 2019-01-28 | 2021-10-05 | Board Of Regents, The University Of Texas System | Método para tratar uma doença em um sujeito mamífero, método para reduzir ou eliminar uma ou mais mutações ou anormalidades citogenéticas nas células cancerosas de um sujeito com câncer, método para diagnosticar um sujeito com uma doença proliferativa responsiva à terapia de quelação, método para diagnosticar e tratar um sujeito com uma doença proliferativa responsiva à terapia de quelação, composição farmacêutica ou combinação farmacêutica, quelante de metal, terapia anticâncer, e antioxidante e/ou mineral |
| CN110123825B (zh) * | 2019-05-28 | 2021-11-30 | 宁波市鄞州人民医院 | 一种包含去甲氧柔红霉素的药物组合物 |
| CA3199623A1 (en) * | 2020-10-27 | 2022-05-05 | Vor Biopharma Inc. | Compositions and methods for treating hematopoietic malignancy |
| WO2025214401A1 (zh) * | 2024-04-12 | 2025-10-16 | 四川科伦博泰生物医药股份有限公司 | 抗体药物偶联物、组合物及其用途和方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744460A (en) * | 1996-03-07 | 1998-04-28 | Novartis Corporation | Combination for treatment of proliferative diseases |
| US20020103141A1 (en) * | 1998-12-23 | 2002-08-01 | Mckearn John P. | Antiangiogenic combination therapy for the treatment of cancer |
| EP1309627B1 (en) * | 2000-08-08 | 2009-09-30 | Immunomedics, Inc. | Immunotherapy for chronic myelocytic leukemia with naked anti-nca-90 antibody |
-
2002
- 2002-11-06 WO PCT/US2002/035532 patent/WO2004043461A1/en not_active Ceased
- 2002-11-06 BR BR0215935-0A patent/BR0215935A/pt not_active IP Right Cessation
- 2002-11-06 AU AU2002348178A patent/AU2002348178A1/en not_active Abandoned
- 2002-11-06 MX MXPA05004711A patent/MXPA05004711A/es active IP Right Grant
- 2002-11-06 CN CNA028301404A patent/CN1720044A/zh active Pending
- 2002-11-06 JP JP2004551359A patent/JP2006508119A/ja active Pending
- 2002-11-06 CA CA002504611A patent/CA2504611A1/en not_active Abandoned
- 2002-11-06 EP EP02784400A patent/EP1575582A4/en not_active Withdrawn
-
2005
- 2005-04-25 CR CR7804A patent/CR7804A/es not_active Application Discontinuation
- 2005-04-25 NO NO20052009A patent/NO20052009L/no not_active Application Discontinuation
-
2010
- 2010-03-22 AU AU2010201113A patent/AU2010201113A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002348178A1 (en) | 2004-06-03 |
| CN1720044A (zh) | 2006-01-11 |
| CA2504611A1 (en) | 2004-05-27 |
| MXPA05004711A (es) | 2005-08-03 |
| AU2010201113A1 (en) | 2010-04-15 |
| WO2004043461A1 (en) | 2004-05-27 |
| NO20052009D0 (no) | 2005-04-25 |
| CR7804A (es) | 2008-10-29 |
| EP1575582A4 (en) | 2009-03-11 |
| JP2006508119A (ja) | 2006-03-09 |
| BR0215935A (pt) | 2005-08-09 |
| EP1575582A1 (en) | 2005-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007022073A3 (en) | Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives | |
| EP4424372A3 (en) | Compounds and methods for treatment of viral infections | |
| NZ543867A (en) | Modified fluorinated nucleoside analogues | |
| BR0215935A (pt) | Terapia combinada para tratamento de leucemia aguda e sìndrome mielodisplásica | |
| CY1113012T1 (el) | Λιποσωμικες φαρμακοτεχνικες μορφες παραγοντων ανθρακυκλινης και αναλογων κυτιδινης | |
| AP2005003211A0 (en) | 1'-,2'-and 3'-modified nucleoside derivatives for treating flaviviridae infections. | |
| ES2138969T3 (es) | Combinacion de nucleosidos antivirales. | |
| DK1644392T3 (da) | Kulhydratderivater af rapamycin | |
| BRPI9809791B8 (pt) | compostos imuno efetores de fosfato de aminoalquil glucosamina e composições compreendendo os mesmos | |
| DK0526537T3 (da) | 5-Benzylbarbituratderivater | |
| WO2003099346A3 (en) | Compositions and methods for coating medical implants | |
| DK1412368T3 (da) | Sukkerderivater af hydromorfon, dihydromorfin, dihydroisomorfin, sammensætninger deraf og anvendelser til behandling eller forebyggelse af smerter | |
| RS20120201A3 (en) | Methods and compositions for hepatitis c virus treatment | |
| MX2009012155A (es) | Combinación farmacéutica sinérgica para el tratamiento de cáncer. | |
| NO20062398L (no) | Daglig, oral, kontrollert frigivnings oksycodon-doserings form | |
| BRPI0503981A (pt) | substituto do açúcar apetecìvel, de baixa caloria com agente de volume insolúvel em água | |
| WO2004028475A3 (en) | Glycosylceramide analogues | |
| PT1368041E (pt) | Composicao aquosa de anfotericina | |
| BR9908391A (pt) | Composição antitumural contendo uma combinação sinergìstica de um derivado de antraciclina com um derivado de camptotecina | |
| DK1216256T3 (da) | Makrolid-antibiotika og behandling af pasteurellosis | |
| WO2008104893A3 (en) | Nucleoside derivatives useful for the treatment or prevention of viral infections and methods of use thereof | |
| DK1079840T3 (da) | Synergistisk præparat af inulin og et anticancerlægemiddel til anvendelse til behandling af cancer | |
| UA83204C2 (ru) | Комбинированная терапия для лечения острого лейкоза и миелодиспластичного синдрома | |
| BRPI0518700A2 (pt) | combinaÇÕes antitumorais, contendo um agente inibidor de vegf e 5fu ou um de seus derivados | |
| EP4464701A4 (en) | 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING IT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |